Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Mar 15;5(6):735-738.
doi: 10.1002/ccr3.881. eCollection 2017 Jun.

Ibrutinib-induced severe liver injury

Amara G Nandikolla  1 , Olga Derman  1 , Deborah Nautsch  2 , Qiang Liu  2 , Hatef Massoumi  3 , Sangeetha Venugopal  4 , Ira Braunschweig  1 , Murali Janakiram  1
Affiliations
Case Reports

Ibrutinib-induced severe liver injury

Amara G Nandikolla et al. Clin Case Rep. .

Abstract

Ibrutinib, an inhibitor of the Bruton's tyrosine kinase of the B-cell receptor pathway, is an effective therapeutic agent for B-cell lymphomas. As these drugs are novel, long-term or rare adverse events are not yet known. We report the first case of ibrutinib-induced severe liver injury in a patient with relapsed/refractory CLL.

Keywords: Chronic lymphocytic leukemia; Richter's syndrome; ibrutinib; liver injury; tyrosine kinase inhibitors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Liver biopsy: There is marked hepatocellular and canalicular cholestasis around the central veins associated with hepatocyte injury and acidophil bodies. These findings are compatible with a cholestatic pattern of drug‐induced liver injury.
See this image and copyright information in PMC

References

    1. Wang, Y. , Zhang L. L., Champlin R. E., and Wang M. L.. 2015. Targeting Bruton's tyrosine kinase with ibrutinib in B‐cell malignancies. Clin. Pharmacol. Ther. 97:455–468. - PubMed
    1. Byrd, J. C. , Brown J. R., O'Brien S., Barrientos J. C., Kay N. E., Reddy N. M., et al. 2014. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N. Engl. J. Med. 371:213–223. - PMC - PubMed
    1. Byrd, J. C. , Furman R. R., Coutre S. E., Flinn I. W., Burger J. A., Blum K. A., et al. 2013. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369:32–42. - PMC - PubMed
    1. de Claro, R. A. , McGinn K. M., Verdun N., Lee S. L., Chiu H. J., Saber H., et al. 2015. FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia. Clin. Cancer Res. 21:3586–3590. - PubMed
    1. Wang, M. L. , Rule S., Martin P., Goy A., Auer R., Kahl B. S., et al. 2013. Targeting BTK with ibrutinib in relapsed or refractory mantle‐cell lymphoma. N. Engl. J. Med. 369:507–516. - PMC - PubMed

Publication types

LinkOut - more resources